DKAH 269

Drug Profile

DKAH 269

Alternative Names: DKAH 269 CL

Latest Information Update: 11 Feb 2000

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Boehringer Ingelheim
  • Developer Boehringer Ingelheim; Boehringer Ingelheim Pharma KG
  • Class Anti-ischaemics; Antiarrhythmics
  • Mechanism of Action Potassium channel antagonists; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Ischaemic heart disorders; Tachycardia

Most Recent Events

  • 11 Feb 2000 No-Development-Reported for Ischaemic heart disorders in Germany (Unknown route)
  • 11 Feb 2000 No-Development-Reported for Tachycardia in Germany (Unknown route)
  • 27 Feb 1997 Preclinical development for Ischaemic heart disorders in Germany (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top